ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE
Clinical safety rating: safe
Animal studies have demonstrated safety
Albuterol is a beta-2 adrenergic receptor agonist that relaxes bronchial smooth muscle. Ipratropium bromide is an anticholinergic agent that inhibits muscarinic receptors, reducing bronchoconstriction and mucus secretion.
| Metabolism | Albuterol is metabolized primarily by sulfotransferase (SULT1A3) to an inactive sulfate conjugate. Ipratropium bromide is partially hydrolyzed to inactive metabolites and has minimal hepatic metabolism. |
| Excretion | Albuterol: 60-70% renal as unchanged drug and metabolites (primarily sulfate conjugate), 10-20% fecal. Ipratropium: 50-60% fecal (unabsorbed), 30-40% renal (metabolites); minimal renal excretion of unchanged drug. |
| Half-life | Albuterol: 3-6 hours (terminal half-life), prolonged in hepatic or renal impairment. Ipratropium: 1.5-2 hours (terminal half-life), clinical effects persist longer due to receptor binding. |
| Protein binding | Albuterol: ~10% bound to albumin. Ipratropium: 30-40% bound to alpha-1-acid glycoprotein. |
| Volume of Distribution | Albuterol: 1.5-2 L/kg. Ipratropium: 2-4 L/kg. Both indicate extensive tissue distribution. |
| Bioavailability | Inhalation: Albuterol 10-20% (systemic), Ipratropium 1-3% (minimal systemic absorption). Oral albuterol ~50% but not used in combination. |
| Onset of Action | Inhalation: Albuterol 5-15 minutes, Ipratropium 15-30 minutes; peak bronchodilation at 1-2 hours for both. |
| Duration of Action | Inhalation: 4-6 hours for albuterol; 3-4 hours for ipratropium (combination provides up to 6 hours due to additive effects). |
| Molecular Weight | Albuterol sulfate: 576.7 Da; Ipratropium bromide: 430.4 Da (combined product). |
Two inhalations (albuterol 90 mcg and ipratropium 18 mcg per inhalation) four times daily via oral inhalation. Maximum: 12 inhalations per day.
| Dosage form | SOLUTION |
| Renal impairment | No specific dose adjustment required for renal impairment. Use with caution in severe renal impairment (eGFR < 30 mL/min) due to potential for systemic accumulation of ipratropium. |
| Liver impairment | No specific dose adjustment required for hepatic impairment. Use with caution in severe hepatic impairment (Child-Pugh class C) due to limited data. |
| Pediatric use | Not recommended for pediatric patients under 4 years of age. For children 4 years and older: Two inhalations (albuterol 90 mcg and ipratropium 18 mcg per inhalation) four times daily as needed. |
| Geriatric use | No specific dose adjustment required, but caution advised due to increased risk of anticholinergic side effects (e.g., dry mouth, urinary retention) and potential for reduced renal function. Initial dosing at lower end of range (e.g., two inhalations twice daily) may be considered. |
| 1st trimester | Albuterol and ipratropium are generally not recommended during first trimester unless benefit outweighs risk; limited human data show no consistent teratogenicity. |
| 2nd trimester | Use with caution; may cause fetal tachycardia or hypoglycemia with maternal beta-agonist use; ipratropium has minimal systemic absorption. |
| 3rd trimester | Use with caution; beta-agonists may inhibit uterine contractions and cause fetal tachycardia; ipratropium is poorly absorbed. |
Clinical note
Other anticholinergic drugs can have additive effects Can cause paradoxical bronchospasm and narrow-angle glaucoma.
| Placental transfer | Albuterol crosses placenta; ipratropium likely crosses minimally due to low bioavailability. |
| Breastfeeding | Albuterol and ipratropium are excreted into breast milk in low amounts; albuterol may cause infant agitation; ipratropium is poorly absorbed orally; compatible with breastfeeding with monitoring for infant side effects. |
■ FDA Black Box Warning
None
| Common Effects | asthma |
| Serious Effects |
Hypersensitivity to albuterol, ipratropium, or atropineHistory of hypersensitivity to soya lecithin or peanuts (due to propellant in some formulations)
| Precautions | Paradoxical bronchospasm, Immediate hypersensitivity reactions, Excessive use may lead to cardiovascular effects including increased heart rate and blood pressure, Use caution in patients with cardiovascular disorders, seizure disorders, and hyperthyroidism, Do not use for acute episodes of COPD or asthma, Not for use as monotherapy in asthma |
| Food/Dietary | No specific food interactions. Caffeine may increase stimulant effects. Avoid alcohol as it may worsen side effects. |
Loading safety data…
| Lactation Rating | L2 (Probably Compatible) |
| Teratogenic Risk | Albuterol sulfate and ipratropium bromide combination: Albuterol (FDA Pregnancy Category C): Animal studies show cleft palate at high doses; human data suggest increased risk of congenital anomalies (gastroschisis, cleft palate) when used orally or intravenously in first trimester, but inhaled doses associated with minimal risk. No adequate human studies for ipratropium (FDA Pregnancy Category B). Inhaled combination not associated with major malformations in second/third trimester. First trimester: Consider potential risk of orofacial clefts. Second/third trimester: Generally considered safe; monitor for maternal tachycardia and fetal tachyarrhythmia. |
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, and respiratory function. In pregnancy, assess fetal heart rate and uterine activity (especially with high doses or intravenous use). Consider growth scans if prolonged use. No specific fetal monitoring required for standard inhaled doses. |
| Fertility Effects | No established adverse effects on fertility in humans. Animal studies with albuterol show no impairment of fertility at inhaled doses. Ipratropium has no known fertility effects. |
| Clinical Pearls | Albuterol sulfate and ipratropium bromide combination is used for COPD exacerbations. Albuterol is a beta-2 agonist; ipratropium is an anticholinergic. Shake well before use. Rinse mouth after inhalation to prevent thrush. Not for acute asthma attacks as monotherapy. Monitor for paradoxical bronchospasm. Can cause dry mouth, cough, and nervousness. Avoid contact with eyes; ipratropium may cause blurred vision or eye pain. |
| Patient Advice | Shake the inhaler well before each use. · Rinse your mouth with water after using to reduce dry mouth and hoarseness. · Do not use more often than prescribed; overuse can increase side effects. · Avoid spraying into eyes; if contact occurs, flush with water and seek medical help if vision changes. · Seek immediate medical attention if you have worsening breathing, hives, or swelling. · Store at room temperature away from heat and open flames (contents under pressure). |